Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
- PMID: 33547248
- DOI: 10.1158/1535-7163.MCT-20-1028
Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Erratum for
-
MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.Mol Cancer Ther. 2017 Apr;16(4):739-751. doi: 10.1158/1535-7163.MCT-16-0591. Epub 2017 Jan 9. Mol Cancer Ther. 2017. PMID: 28069878
References
-
- Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16:739–51.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
